NeuBase Therapeutics, Inc. Quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD from Q3 2015 to Q3 2022

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary
NeuBase Therapeutics, Inc. quarterly Deferred Tax Assets, Operating Loss Carryforwards history and growth rate from Q3 2015 to Q3 2022.
  • NeuBase Therapeutics, Inc. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending September 30, 2022 was $22.5M, a 69.5% increase year-over-year.
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2022 $22.5M +$9.21M +69.5% Sep 30, 2022 10-K 2022-12-21
Q3 2021 $13.3M +$7.48M +130% Sep 30, 2021 10-K 2022-12-21
Q3 2020 $5.77M +$3.69M +178% Sep 30, 2020 10-K 2021-12-23
Q3 2019 $2.08M +$2.07M +17359% Sep 30, 2019 10-K 2020-12-23
Q3 2018 $11.9K* Sep 30, 2018 10-K 2020-01-10
Q3 2016 $40.8M +$20M +96.6% Sep 30, 2016 10-K 2016-12-22
Q3 2015 $20.7M Sep 30, 2015 10-K 2016-12-22
* An asterisk sign (*) next to the value indicates that the value is likely invalid.